Bio-Techne Corp SG&A Expenses 2010-2025 | TECH

Bio-Techne Corp sg&a expenses for the twelve months ending March 31, 2025 were $0.525B, a 25.22% increase year-over-year.

  • Bio-Techne Corp annual sg&a expenses for 2024 were $0.466B, a 23.26% increase from 2023.
  • Bio-Techne Corp annual sg&a expenses for 2023 were $0.378B, a 1.51% increase from 2022.
  • Bio-Techne Corp annual sg&a expenses for 2022 were $0.373B, a 14.71% increase from 2021.

Bio-Techne Corp SG&A Expenses 2010-2025 | TECH

  • Bio-Techne Corp annual sg&a expenses for 2024 were $0.466B, a 23.26% increase from 2023.
  • Bio-Techne Corp annual sg&a expenses for 2023 were $0.378B, a 1.51% increase from 2022.
  • Bio-Techne Corp annual sg&a expenses for 2022 were $0.373B, a 14.71% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$226.4B
Amgen (AMGN)$166.3B
Gilead Sciences (GILD)$141.3B
Vertex Pharmaceuticals (VRTX)$122.5B
Bristol Myers Squibb (BMY)$99.7B
CSL (CSLLY)$85.2B
GSK (GSK)$77.9B
Regeneron Pharmaceuticals (REGN)$61.8B
Alnylam Pharmaceuticals (ALNY)$42.5B
Argenex SE (ARGX)$35.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.2B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.2B
Illumina (ILMN)$16.6B
Genmab (GNMSF)$14.9B
Genmab (GMAB)$14.7B
Incyte (INCY)$13.7B
Moderna (MRNA)$13.4B
Exelixis (EXEL)$12.4B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B
Regencell Bioscience Holdings (RGC)$7.3B